You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》麥格理升綠葉製藥(02186.HK)評級至「跑贏大市」 目標價上調至7.6元
阿思達克 06-16 10:45
麥格理發表報告表示,隨著綠葉製藥(02186.HK)有更多候選藥物進入臨床階段,預期會出現跨不同治療領域的更多元化產品線組合,該行將其5種發展中藥物加入作研究,預期該等藥物將於2023至2024年推出市場,收益最高達35億元人民幣。

該行補充,綠葉製藥短期盈利受到藥品集中採購(GPO)所影響,且下調其2020至2022年盈利測18%/4%/10%,惟目標價由4.5元升至7.6元,評級亦由「中性」上調至「跑贏大市」,相信現價尚未完全反映其未來5年研發之13種創新藥物。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account